Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Benadryl for infants

This article was originally published in The Tan Sheet

Executive Summary

Only one in 22 infants who were given Pfizer's Benadryl (diphenhydramine) to aid with sleep saw an improvement in their condition compared to three of 22 infants taking placebo, a study in the July Archives of Pediatrics & Adolescene Medicine finds. Dan Merenstein, MD, Johns Hopkins University, et al., conducted a double-blind, randomized, controlled clinical trial of the 44 children, ages 6 months to 15 months. Placebo or diphenhydramine was given to the babies 30 minutes before anticipated bed time. Parents reported on the number of night awakenings requiring parental assistance during a week of drug treatment and 2-4 weeks after its discontinuation. Secondary outcomes included parental overall happiness with sleep and improved sleep latency. The data safety monitoring board voted unanimously to stop the trial because of lack of effectiveness of diphenhydramine over placebo...

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS099533

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel